Crutel, Véronique
Lambert, Estelle
Penelaud, Pierre-François
Albarrán Severo, Cristina
Fuentes, Joaquin http://orcid.org/0000-0001-5488-5543
Rosier, Antoine
Hervás, Amaia
Marret, Stéphane
Oliveira, Guiomar
Parellada, Mara
Kyaga, Simon
Gouttefangeas, Sylvie
Bertrand, Marianne
Ravel, Denis
Falissard, Bruno
Funding for this research was provided by:
Servier
Article History
First Online: 5 November 2020
Change Date: 24 March 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10803-020-04822-8
Compliance with Ethical Standards
:
: VC, EL, P-FP, CAS, SK, SG, and MB are employees of Servier. BF has been consultant for Actelion, Allergan, Almirall, Astellas, AstraZeneca, Bayer, Biotronik, BMS, Boehringer Ingelheim, Daiichi- Sankyo, Eli Lilly, Genzyme, Gilead, Grunenthal, GSK, HRA, Janssen, Lundbeck, MSD, Novartis, Otsuka, Pierre Fabre, Roche, Sanofi, Servier, Stallergene, UCB, ViiV. JF has received research support from Servier and AIMS-2-Trials project ID 777394. DR is an employee of Neurochlore. GO, SM, AR, AH, and MP report no conflict of interest.
: The studies will be carried out in compliance with the protocol, Good Clinical Practice guidelines, the ethical principles that have their origin in the Declaration of Helsinki and the applicable regulatory requirements.
: Informed assent/consent of the patient and parents/legal representative(s) or caregivers (where applicable) is collected for every patient at the selection visit, before any study-related procedures are carried out.